While our initial dataset focused only on primary tumor burden, future melanoma studies will include testing in additional models, i.e., patient-derived xenograft models with clinically relevant genetic alterations (e.g., BRAF, MEK, and NRAS mutations), metastasis models, and syngeneic models in conjunction with immunotherapy (e.g., anti-PD-1, anti-CTLA-4). This evidence concerns the gene MAP2K7 and melanoma.